A wide-moat Blue Cross franchise at a trough multiple—if CMS clears and Medicaid rates catch up, Carelon can re-rate Elevance from insurer to services platform.
Elevance Health Inc. (ELV), formerly operating under the Anthem brand, functions as a dominant force in the United States managed care sector, providing health insurance and medical services to over 45 million members.[1, 2] The organization is architected around a dual-segment model that distinguishes between its legacy insurance operations—the Health Benefits segment—and its high-growth, high-margin services division, Carelon.[3, 4] The primary revenue generation mechanism involves the collection of monthly premiums from individuals, employer groups, and government entities, alongside a scaling stream of service-related fees and pharmacy product revenue from CarelonRx.[3, 5]
The core products of the Health Benefits segment include health maintenance organization (HMO) and preferred provider organization (PPO) plans, specialized government programs such as Medicare Advantage and Medicaid, and BlueCard® services that leverage the national Blue Cross Blue Shield network.[3, 6, 7] These products cater to a diverse customer base, including small and large corporations, state governments seeking to manage Medicaid populations, and seniors transitioning to privatized Medicare solutions.[3, 4] The enterprise distinguishes itself from rivals through its exclusive Blue Cross Blue Shield (BCBS) licenses in 14 states, which provide an unparalleled local brand moat and deep provider relationships that are difficult for national competitors to replicate.[2, 8]
Elevance Health is currently navigating a significant strategic pivot, characterized by management as a "trough year" in 2026.[9, 10] This period involves an intentional trade-off where the company is sacrificing short-term membership growth in government programs to reset margins and reposition the portfolio for a 12% plus adjusted earnings per share (EPS) growth algorithm starting in 2027.[1, 11] The organization is also absorbing the impact of a material regulatory notice from the Centers for Medicare & Medicaid Services (CMS) regarding historical risk-adjustment data, which led to a $935 million accrual in the first quarter of 2026.[12]
Despite these headwinds, the latest financial results for the first quarter of 2026—announced on April 22, 2026—showed resilience, with adjusted diluted EPS of $12.58 beating consensus expectations, primarily supported by strong investment income and disciplined administrative spending.[6, 13] The investment thesis centers on the durability of the core BCBS franchise and the latent earnings power of the Carelon platform as it shifts from an internal service provider to an external-facing healthcare services giant.[14, 15]
| Segment | Primary Revenue Driver | Key Customer Type |
|---|---|---|
| Health Benefits | Medical Premiums | Employers, State Govs, Seniors |
| CarelonRx | Pharmacy Product Sales | Health Plans, Self-Insured Corps |
| Carelon Services | Fee-for-Service & Risk-Based Fees | Health Plans, High-Acuity Patients |
Strategic Transition Underway
The economic engine of Elevance Health is currently undergoing a structural transformation from a traditional health insurer into a "whole health" company. This evolution is driven by the need to capture a larger share of the healthcare value chain, moving beyond simple risk aggregation toward active care delivery and specialized service management.
The organization’s product suite is bifurcated into two reporting segments that operate with increasing synergy. The Health Benefits segment manages the risk-bearing activities, offering Individual and Employer Group plans that range from fully insured products to Administrative Services Only (ASO) arrangements.[3, 4] In ASO models, Elevance provides the network and claims processing for a fee, while the employer retains the risk of medical costs—a strategy that has become vital for preserving margins in an inflationary environment.[3, 6] The government business sub-segment represents a massive portion of the enterprise, with Medicaid and Medicare Advantage (MA) serving as the primary growth engines over the last decade.[3, 16]
Carelon, the healthcare services brand, is the strategic center of gravity for future margin expansion. It is divided into CarelonRx and Carelon Services.[1, 3, 4] CarelonRx functions as the PBM, managing nearly four billion prescriptions annually across the U.S. and leveraging its scale to negotiate significant drug rebates.[5, 17] Carelon Services focuses on complex care areas like behavioral health, oncology, and home health.[18, 19] By integrating these services, Elevance aims to "internalize" medical spending. When a Health Benefits member uses a Carelon behavioral health clinic, the enterprise converts a medical expense into a service-segment revenue stream, effectively capturing the margin that would otherwise leak to external providers.[14, 15]
Elevance Health maintains a formidable moat characterized by several structural advantages:
The market opportunity for Elevance is expanding due to secular trends in U.S. healthcare. The global PBM market is projected to grow at a 5.5% CAGR to nearly $1 trillion by 2034, driven by the proliferation of high-cost specialty drugs.[5] CarelonRx is positioned to capture this growth, particularly as specialty pharmacy services are expected to dominate the market share.[5]
Simultaneously, the behavioral health market is witnessing an unprecedented surge in demand. Estimates suggest 25% of Americans will need behavioral health services by 2026, and the overall market size is expected to reach $197.59 billion by 2030.[19, 22] Carelon Behavioral Health is already one of the largest providers in this space, and its ability to prove value through integrated models—where behavioral health support reduces medical ER visits—is a key differentiator.[19, 23]
Elevance Health operates in an oligopolistic environment. Its primary competitor is UnitedHealth Group (UNH), which possesses the highly mature Optum platform.[20, 24] While ELV is "chasing" UNH in terms of service-segment maturity, it is currently "holding ground" in its core insurance markets.[15] Against CVS Health (Aetna), Elevance appears to be "gaining ground" in government programs due to CVS's recent struggles with Medicare Star Ratings and operational consistency.[8]
In the Medicaid space, Elevance is currently "losing ground" on a membership basis due to the deliberate "unwinding" process, where it lost 3.4 million members between 2023 and 2025.[16] however, this is a strategic retreat from lower-margin populations, as the company focuses on "acuity-adjusted" rates where it can maintain profitability.[9, 10]
| Competitor | Market Strength | ELV vs. Competitor Trend |
|---|---|---|
| UnitedHealth (UNH) | Unmatched Scale/Optum | Holding (Chasing Service Maturity) |
| CVS Health (CVS) | Vertical Retail Integration | Gaining (Superior Quality Ratings) |
| Humana (HUM) | Medicare Advantage Focus | Holding (Priority on Margin Over Growth) |
| Centene (CNC) | Medicaid Dominance | Gaining (Better Vertical Synergy) |
Moat-Protected Service Evolution
The financial profile of Elevance Health is currently defined by two disparate forces: strong top-line revenue growth and acute margin pressure within its government-sponsored insurance business.
The company reported its first-quarter 2026 results on April 22, 2026.[25, 26] These results were pivotal in clarifying the trajectory of the "trough year."
The Health Benefits segment saw Q1 2026 revenue of $42.5 billion (+2.6%), but operating gain fell 2.7% as higher medical costs in Medicaid outpaced premium increases.[6, 28] Medical membership stood at 45.4 million, a sequential increase of 200,000 from year-end 2025, driven by commercial fee-based growth that offset losses in MA and Medicaid.[6, 29, 30]
Carelon reported Q1 2026 revenue of $18.0 billion (+7.9%), but operating gain declined 3.8% to $1.1 billion.[6, 28] This decline was attributed to "lower health plan membership" (as Health Benefits members left) and continued heavy investment in risk-based capabilities for Carelon Services.[6, 28]
Elevance Health’s current valuation is compressed by regulatory uncertainty and the 2026 "earnings trough." At a share price of approximately $333.50, the stock trades at roughly 12.5x its $26.75 adjusted EPS guidance.[31, 32] This is a meaningful discount to its 5-year historical average P/E of ~15x-17x.[14, 33]
The most critical financial drivers for valuation over the next 5 years include:
1. Sales Growth: 5-year sales growth has historically averaged 9% per year.[34] Looking forward, revenue growth is expected to moderate to a 6-8% CAGR as the company focuses on margin over volume in its government business.[14, 33]
2. Margin Recovery: Management expects the Medicaid operating margin to hit a trough of -1.75% in 2026.[9, 10] Reaching a normalized 2-3% margin in this segment by 2028 is a prerequisite for the 12% EPS growth target.
3. Capital Allocation: The company plans to repurchase at least $2.3 billion in shares in 2026.[9, 33] With a payout ratio of ~27%, the dividend is highly secure and has a 5-year growth rate of 12.7%.[32, 35]
4. Carelon Multiplier: As Carelon’s external revenue pipeline scales—particularly in oncology and severe mental illness—the segment could eventually command a services-level multiple (20x+) vs. the insurance-level multiple (12x-15x) currently applied to the consolidated entity.[14, 36]
| Metric | FY 2025 (Actual) | FY 2026 (Projected) |
|---|---|---|
| Operating Revenue | $197.6B | ~$194B - $196B |
| Adjusted Diluted EPS | $30.29 | at least $26.75 |
| Operating Cash Flow | $4.3B | at least $5.5B |
| Benefit Expense Ratio | 90.0% | ~90.2% |
Valuation Anchored to Recovery
The investment thesis for Elevance Health is subject to a range of risks that span from administrative errors to tectonic shifts in federal healthcare policy.
Regulatory Overhang is Key
Our 5-year projections are based on the company's transition from the 2026 trough toward its long-term growth algorithm.
In this scenario, Elevance resolves the CMS sanctions with a settlement near the current accrual and returns to its 12% EPS growth target in 2027.[1, 11]
* Revenue Growth: 6.5% CAGR, driven by mid-single-digit pricing power and Carelon expansion.[14, 33]
* Margins: Consolidated operating margins recover from ~3.8% to 5.2% by Year 5 as Carelon Services scales to external clients.[14, 44]
* EPS Trajectory: 2026 EPS of $26.75, jumping to $30.00 in 2027, then growing at 10% thereafter.
* Valuation: 15x exit P/E multiple, reflecting a return to historical averages once regulatory clouds disperse.[33]
* Implied Share Price (Year 5): $652.50.
In this scenario, Carelon outpaces Optum's growth rates, and Medicaid rates align perfectly with acuity.
* Revenue Growth: 9% CAGR, with Carelon Services capturing significant external market share in behavioral health.[19, 22]
* Margins: Margins reach 6.0% as the high-margin Carelon segment becomes 40% of total operating gain.[14, 44]
* EPS Trajectory: 14% annual EPS growth post-2026.
* Valuation: 18x exit multiple, as the market re-rates ELV as a high-growth healthcare services firm.[14]
* Implied Share Price (Year 5): $891.00.
In this scenario, CMS sanctions extend for years, and PBM legislation significantly impacts CarelonRx margins.
* Revenue Growth: 3% CAGR, struggling with membership losses.[33]
* Margins: Margins remain pinned below 4% due to Medicaid rate inadequacy.[9, 10]
* EPS Trajectory: 5% annual growth, hindered by slow buybacks.
* Valuation: 11x exit multiple, reflecting a permanent "regulatory trap" discount.
* Implied Share Price (Year 5): $374.00.
| Scenario | Rev Year 5 ($B) | Margin / EPS Year 5 | Exit Multiple | Current Price | Implied Price | 5-Yr Tot Ret | Ann Ret | Prob |
|---|---|---|---|---|---|---|---|---|
| High | $303.0 | $49.50 | 18.0x | $333.50 | $891.00 | 167% | 21.7% | 25% |
| Base | $271.0 | $43.50 | 15.0x | $333.50 | $652.50 | 96% | 14.4% | 60% |
| Low | $228.0 | $34.00 | 11.0x | $333.50 | $374.00 | 12% | 2.3% | 15% |
Probability-Weighted Price Target (5-Year): $670.35
RECOVERY UPSIDE POTENTIAL
| Metric | Score | Narrative |
|---|---|---|
| Management Alignment | 9 | CEO Gail Boudreaux owns ~$46M in stock; 93% of her pay is performance-based, directly tied to shareholder returns.[45, 46] |
| Revenue Quality | 8 | Highly recurring premium revenue from government and enterprise clients. Risk exists in government contract renewals.[3, 16] |
| Market Position | 7 | #2 national insurer with a massive brand moat. Currently "right-sizing" and shedding lower-quality members.[2, 29, 39] |
| Growth Outlook | 8 | Carelon represents a huge addressable market in behavioral health and oncology that is still in early-stage scaling.[5, 19, 22] |
| Financial Health | 8 | Solid 1.5x current ratio and $2.2B parent-company cash. "GOOD" health score on InvestingPro.[13, 32] |
| Business Viability | 9 | Healthcare is non-discretionary. BCBS licenses create a structural barrier that is virtually impossible for new entrants to overcome.[2, 8] |
| Capital Allocation | 9 | Disciplined focus on buybacks ($2.3B in 2026) and 15 years of dividend growth.[1, 9, 13] |
| Analyst Sentiment | 6 | "Hold" consensus due to near-term Medicaid/CMS risks. Street is in "wait and see" mode.[32, 47] |
| Profitability | 7 | Net margin (2.8%) is below peers but possesses significant upside if Carelon efficiency moves to peer-level ( Optum).[8, 14, 24] |
| Track Record | 8 | Consistent history of meeting long-term targets despite periodic sector-wide volatility.[34, 48] |
Blended Score: 7.9/10
DURABLE VALUE PLAY
The investment thesis for Elevance Health is centered on a classic "time horizon arbitrage." While the market is correctly identifying near-term pressures in the Medicaid "unwinding" and the CMS risk-adjustment probe, it appears to be underestimating the structural earnings power of a fully integrated Carelon-Health Benefits ecosystem. The company is deliberately sacrificing membership today to ensure a more profitable and stable member base tomorrow, a move that is typical of the "pricing discipline" that has characterized Gail Boudreaux's tenure.[9, 10, 29]
Key catalysts to watch over the next 12 months include:
1. CMS Resolution: A final settlement that removes the threat of an enrollment freeze.[36, 40]
2. Medicaid Margin Stabilization: Evidence that state rate increases are beginning to catch up with member acuity.[9, 10]
3. Carelon External Wins: Announcement of major third-party PBM or behavioral health contracts outside of the core Blue Cross network.[9, 14]
In summary, Elevance Health is currently a "wide-moat" enterprise trading at a "trough multiple." For investors with a 3-5 year perspective, the current price levels likely represent a compelling entry point into one of the most durable cash-flow engines in the healthcare sector.
VALUE TROUGH OPPORTUNITY
ELV is currently showing mixed technical signals. The stock is trading near $333.50, which is slightly above its 200-day moving average of $331.60 and significantly above its 50-day average of $308.88.[31, 32] While the short-term momentum is positive following the Q1 earnings beat, the long-term trend remains down from its 52-week high of $432.93.[31, 49] The stock faces immediate resistance at the $339 level, with strong support at the $318 mark.[49] In the short term, expect range-bound trading as investors digest the raised guidance against the looming May 30 CMS sanction deadline.[36, 40]
STABILIZING MOMENTUM PENDING
View Elevance Health, Inc. (ELV) stock page
Loading the interactive version of this report…